# Construction and Evaluation of Multitracer Small-Animal PET Probabilistic Atlases for Voxel-Based Functional Mapping of the Rat Brain

Cindy Casteels<sup>1</sup>, Peter Vermaelen<sup>1</sup>, Johan Nuyts<sup>1</sup>, Annemie Van Der Linden<sup>2</sup>, Veerle Baekelandt<sup>3</sup>, Luc Mortelmans<sup>1</sup>, Guy Bormans<sup>4</sup>, and Koen Van Laere<sup>1</sup>

<sup>1</sup>Division of Nuclear Medicine, University Hospital Gasthuisberg and Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>Bio-Imaging Laboratory, University of Antwerp, Antwerp, Belgium; <sup>3</sup>Laboratory for Neurobiology and Gene Therapy, Molecular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; and <sup>4</sup>Laboratory of Radiopharmaceutical Chemistry, Katholieke Universiteit Leuven, Leuven, Belgium

Automated voxel-based or predefined volume-of-interest (VOI) analysis of rodent small-animal PET data is necessary for optimal use of information because the number of available resolution elements is limited. We have mapped metabolic (18F-FDG), dopamine transporter (DAT) (2'-18F-fluoroethyl(1R-2-exo-3exe)-8-methyl-3-(4-chlorophenyl)-8-azabicyclo[3.2.1]-octane-2-carboxylate [18F-FECT]), and dopaminergic D<sub>2</sub> receptor (11C-raclopride) small-animal PET data onto a 3-dimensional T2-weighted MRI rat brain template oriented according to the rat brain Paxinos atlas. In this way, ligand-specific templates for sensitive analysis and accurate anatomic localization were created. Registration accuracy and test-retest and intersubject variability were investigated. Also, the feasibility of individual rat brain statistical parametric mapping (SPM) was explored for <sup>18</sup>F-FDG and DAT imaging of a 6-hydroxydopamine (6OHDA) model of Parkinson's disease. Methods: Ten adult Wistar rats were scanned repetitively with multitracer small-animal PET. Registrations and affine spatial normalizations were performed using SPM2. On the MRI template, a VOI map representing the major brain structures was defined according to the stereotactic atlas of Paxinos. 18F-FDG data were count normalized to the whole-brain uptake, whereas parametric DAT and D<sub>2</sub> binding index images were constructed by reference to the cerebellum. Registration accuracy was determined using random simulated misalignments and vectorial mismatching. Results: Registration accuracy was between 0.24 and 0.86 mm. For <sup>18</sup>F-FDG uptake, intersubject variation ranged from 1.7% to 6.4%. For <sup>11</sup>Craclopride and <sup>18</sup>F-FECT data, these values were 11.0% and 5.3%, respectively, for the caudate-putamen. Regional testretest variability of metabolic normalized data ranged from 0.6% to 6.1%, whereas the test-retest variability of the caudate-putamen was 14.0% for <sup>11</sup>C-raclopride and 7.7% for <sup>18</sup>F-FECT. SPM analysis of 3 individual 6OHDA rats showed severe hypometabolism in the ipsilateral sensorimotor cortex ( $P \le$ 0.0004) and a striatal decrease in DAT availability ( $P \le 0.0005$ , corrected). Conclusion: MRI-based small-animal PET templates facilitate accurate assessment and spatial localization of rat brain function using VOI or voxel-based analysis. Regional intersubject and test-retest variations found in this study, as well as registration errors, indicate that accuracy comparable to the human situation can be achieved. Therefore, small-animal PET with advanced image processing is likely to play a useful role in detailed in vivo molecular imaging of the rat brain.

**Key Words:** Paxinos atlas; SPM; VOI analysis; microPET; spatial normalization

J Nucl Med 2006; 47:1858-1866

euroimaging studies are increasingly performed on rodents as models for a variety of human diseases and genetic traits. Rodent models of brain disease encompass all major neurodegenerative diseases and stroke, but also psychiatric diseases such as anorexia nervosa, obesity, depression, and anxiety (1,2). Functional small-animal PET imaging allows longitudinal follow-up, which is important when investigating neuropharmacologic interventions or when characterizing diseases. Because the number of available resolution elements is lower in small-animal PET measurements of rodent brain than in the human PET counterpart, optimal use of information is imperative for detailed regional analysis.

An important step in functional neuroimaging analysis is the development of methods to combine data from different subjects into a common atlas space (3). Spatial normalization, using operator-independent voxel-based algorithms, can increase the sensitivity of low-magnitude responses and facilitate group comparisons (4). The group comparisons can be performed using either automated voxel-based or operator-independent volume-of-interest (VOI) analysis on probabilistic atlases that are oriented into a common stereotactic space—for example, according to Talairach and Tournoux for humans (5). For small-animal imaging, a common digital atlas or template to enable spatial normalization of animal brain MR images has been developed for

Received May 30, 2006; revision accepted Aug. 14, 2006.

For correspondence or reprints contact: Cindy Casteels, MSc, Division of Nuclear Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.

E-mail: cindy.casteels@uz.kuleuven.ac.be

COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.

rats (6), baboons (7,8), and macaque brain. Other atlasbased image analysis methods have been developed as well—for example, by means of simulated PET targets (9), derived from a digitized cryosectioned atlas of a single rat and used in combination with predefined VOIs for quantification of small-animal PET data on the rat brain.

Extension to automated whole-brain analysis methods, either by predefined VOI analysis or by statistical parametric mapping (SPM), has not been systematically investigated. Especially in SPM, voxel-based analysis may offer a unique way of extracting information in a fully automated data-driven approach, which has been shown to be superior in detecting pathologic signals in humans (10).

In the current study, we have used an existing 3-dimensional T2-weighted MRI template, aligned in space with the rat brain atlas of Paxinos (6), onto which we have mapped functional metabolic (18F-FDG), dopamine transporter (DAT) (using 2'-18F-fluoroethyl(1R-2-exo-3-exe)-8-methyl-3-(4-chlorophenyl)-8-azabicyclo[3.2.1]-octane-2-carboxylate [18F-FECT]), and dopaminergic D<sub>2</sub> receptor (11C-raclopride) small-animal PET data of healthy rat brains to create ligandspecific templates for the assessment of metabolism and dopaminergic neurotransmission and to investigate population variability in radioligand distribution. First, the accuracy of the template registration process was assessed quantitatively for data on normal and lesioned animals. Second, testretest and intersubject variability and right-to-left asymmetry indices were determined for all used radioligands by applying the predefined VOI analysis. Finally, the feasibility of SPM in detailed regional analysis of molecular changes in the rat brain was explored in a model of Parkinson's disease, the 6-hydroxydopamine (6OHDA)–lesioned rat model (11), by studying individual rat brains in comparison to a control group with both DAT and metabolic imaging.

## MATERIALS AND METHODS

#### **Animals**

Ten female Wistar rats (age range, 13–34 wk; body weight range, 242–335 g) were scanned repetitively with 3 radioligands. Furthermore, to demonstrate voxel-based image analysis of the rat brain using functional templates, we studied 3 female 6OHDA-

lesioned Wistar rats (age range, 13–17 wk; body weight range, 230–290 g) 7–11 wk after creating the lesions. The lesions were created by injection of 24  $\mu g$  of 6OHDA (Sigma), dissolved in 3  $\mu L$  of 0.9% sterile NaCl containing 0.1% ascorbic acid, into the right substantia nigra. The injection coordinates were -4.8 mm anteroposterior, 2.1 mm lateral, and 7.2 mm dorsoventral, using bregma as the reference.

All animals were housed 3 to a cage, at an average room temperature of 22.4°C and with illumination available from 8 AM to 8 PM daily. Food and water were given ad libitum. The research protocols were approved by the local Animal Ethics Committee.

## **Tracer Synthesis**


Functional images of the striatal dopamine system were obtained for each rat using the DAT radioligand <sup>18</sup>F-FECT (n = 9, 1 animal died) (12) and the D<sub>2</sub> receptor radioligand <sup>11</sup>C-raclopride (n = 10) (13). Metabolic images were obtained using <sup>18</sup>F-FDG (n = 10).

The <sup>18</sup>F-FECT PET radiotracer was synthesized according to the procedure of Wilson et al. but using 2-<sup>18</sup>F-fluoroethyltrifluoromethanesulfonate instead of 2-<sup>18</sup>F-fluoroethylbromide (*I2*). <sup>11</sup>C-Raclopride was obtained by methylating the corresponding nor-precursor with <sup>11</sup>C-methyltriflate, whereas <sup>18</sup>F-FDG was prepared by using an Ion Beam Applications <sup>18</sup>F-FDG synthesis module. Approximately 18 MBq (500 μCi) of each radioligand (specific activity range, 53–760 GBq/μmol; injection volume, 500 μL) were injected into the tail vein using an infusion needle set.

#### **Data Acquisition**

Small-animal PET imaging was performed using a lutetium oxyorthosilicate detector—based tomograph (microPET Focus 220; Siemens Medical Solutions USA, Inc.), which has a transaxial resolution of 1.35 mm in full width at half maximum. Data were acquired in a  $128 \times 128 \times 95$  matrix with a pixel width of 0.475 mm and a slice thickness of 0.796 mm. The coincidence window width was set at 6 ns. Before being imaged, the rats were anesthetized with an intraperitoneal injection of 50 mg of sodium pentobarbital (Nembutal; Ceva Sante Animale) per kilogram of body weight. All rats were breathing spontaneously throughout the entire experiment.

Time-activity curves for the 3 tracers are shown in Figure 1. For <sup>18</sup>F-FECT, pseudoequilibrium binding was reached approximately 3 h after injection. For atlas creation, static <sup>18</sup>F-FECT measurements were obtained during 40 min starting 3 h after injection. For <sup>18</sup>F-FDG, static acquisitions were performed for 40 min,



**FIGURE 1.** Representative example of time–activity curves for  $^{18}$ F-FECT (A),  $^{11}$ C-raclopride (B), and  $^{18}$ F-FDG (C) expressing regional uptake in striatum ( $\blacktriangle$ ), cerebellum ( $\blacksquare$ ), cortex ( $\blacksquare$ ), and thalamus ( $\blacklozenge$ ). For pre- and postsynaptic dopaminergic ligands, specific-to-nonspecific ratio (striatum to cerebellum [ $\bigcirc$ ]) is also shown.

starting 30 min after injection after overnight fasting (14). Although the time–activity curve for  $^{18}$ F-FDG steadily increases up to 60 min after injection (Fig. 1), we applied an earlier, accurately timed starting point as used in previous literature (15). For  $^{11}$ C-raclopride, dynamic data were acquired during 60 min (frame duration:  $4 \times 15$  s,  $4 \times 60$  s,  $5 \times 180$  s, and  $8 \times 300$  s).

6OHDA-lesioned rats were studied using <sup>18</sup>F-FECT and <sup>18</sup>F-FDG. All animals were scanned in the prone position with their brain centered in the field of view.


For every tracer, several control animals were scanned twice to estimate test–retest variability ( $^{18}$ F-FECT, n=3;  $^{11}$ C-raclopride, n=4;  $^{18}$ F-FDG, n=6). The interval between the 2 scans was 1 d for  $^{18}$ F-FECT and, on average, 6 and 10 wk for  $^{18}$ F-FDG and  $^{11}$ C-raclopride, respectively.

#### **Data Reconstruction**

Small-animal PET studies were reconstructed using both filtered backprojection and a statistical maximum a posteriori probability algorithm (MAP) (18 iterations,  $\beta=0.5$  resolution) (16). Compared with filtered backprojection, MAP has been shown to result in improved spatial resolution and noise properties on small-animal PET images (17)—an advantage for image registration. On the other hand, filtered backprojection may more accurately estimate radioactivity concentration and was used for quantification. For  $^{11}\text{C}$ -raclopride data, MAP reconstructions were made of only the last 30 min of acquisition time. Randoms correction was performed using a delayed coincidence window; no corrections were made for attenuation or scatter.

#### **Atlas Construction**

The flowchart of the procedure for atlas creation is shown schematically in Figure 2. Construction of the 3-dimensional T2-weighted MRI template, which is aligned in space with the atlas of Paxinos, has previously been described extensively (6). The following within-modality procedure was repeated for all individual <sup>18</sup>F-FECT, <sup>11</sup>C-raclopride, and <sup>18</sup>F-FDG MAP images of



**FIGURE 2.** Schematic representation of construction pathway for functional PET atlases. Solid arrows express the followed procedure; dashed arrows, objective. On standardized atlases, stereotactic grid is shown (2-mm interlines).

healthy subjects. Of the individual PET images, one was selected as the "representative" brain. Each individual PET scan was then transformed into the space of the representative scan. Data voxel size was scaled by a factor of 10 to approximately fit the human brain size so that default parameter settings in SPM could be applied. This within-modality registration of individual data was performed using the sum-of-squared-differences minimization algorithm and 12-parameter affine transformations only in SPM2 (Wellcome Department of Cognitive Neurology), because this provided the best results on a visual basis. The normalized image datasets were averaged voxelwise to create functional image atlases using the SPM Imcalc function.

Cross-modality (<sup>18</sup>F-FDG PET:MRI) and dopaminergic-to-<sup>18</sup>F-FDG atlas registrations to obtain ligand-specific templates mapped in Paxinos space were performed using the mutual information maximization algorithm (*18*), where an adaptation in interpolation method to obtain a smoother cost function is done in SPM2. Consequently, a rat brain spatially normalized to these functional templates will facilitate the reporting of results in coordinates directly corresponding to the Paxinos coordinate system (*6*).

Making use of the stereotactic rat brain atlas of Paxinos, we defined on the MRI template a VOI map representing the major cortical and subcortical structures of the rat brain (5). Each region was primarily defined on horizontal slices, with sagittal and coronal slices used to confirm regional boundaries (PMOD, version 2.65; PMOD Inc.). VOIs were defined separately for the left and right hemispheres and covered 51 slices of the MRI template. VOIs were defined for the rat brain caudate-putamen, globus pallidus, nucleus accumbens, cerebellum, cerebral cortex, thalamus, hypothalamus, hippocampus, pituitary gland, and pons (substantia nigra). The VOIs, superimposed on horizontal slices of the rat brain MRI atlas, are displayed in Figure 3.

### **Data Analysis**

Voxelwise parametric DAT and D<sub>2</sub> binding index images were constructed from original filtered backprojection data by reference to the cerebellum using, for <sup>11</sup>C-raclopride data, the Ichise MRTM2 module in PMOD (19). DAT binding index parametric images were constructed by a voxelwise calculation: (tissue/average activity concentration cerebellum) – 1). <sup>18</sup>F-FDG data were count normalized to the whole-brain uptake. Transformations obtained after mapping individual MAP data to ligand-specific PET templates were passed on to parametric dopaminergic binding index images and <sup>18</sup>F-FDG-filtered backprojection data for quantification purposes.

# **Determination of Registration Accuracy**

The following experiment was performed to quantitatively assess the registration accuracy of mapping individual MAP data to the ligand-specific PET templates. The anatomically standardized image volume from a MAP PET study of a control animal and a 6OHDA-lesioned animal underwent 40 random misalignments each time: 10 translations, 10 rotations, 10 linear stretchings, and 10 combinations of the 3 previous parameters. This was done for all 3 tracers in the case of the control animal and for the <sup>18</sup>F-FECT and <sup>18</sup>F-FDG data in the case of the 6OHDA-lesioned rat. The misalignments were uniformly distributed (random number generation function in Excel 2003; Microsoft) within -5 to +5 mm of translation, -20° to +20° of rotation, and -10% to +10% of scaling along the 3 orthogonal axes/planes. For the combination misalignments, rotations were allowed only within a




FIGURE 3. MRI atlas showing representative horizontal images at multiple levels of rat brain (7 slices apart; radiologic orientation). Many cortical and subcortical structures have been identified: hypothalamus (A), nucleus accumbens (B), globus pallidus (C), pons (substantia nigra) (D), thalamus (E), caudateputamen (F), cerebellum (G), cerebral cortex (H), and hippocampus (I). Also see Table 1.

range of  $10^\circ$  in the 3 main planes. The amount of deliberate misalignment was based on typical magnitudes that can occur in realistic situations. Each resultant image volume was then reregistered to the study-specific template using the automated spatial normalization procedure (12-parameter affine) integrated in SPM2. For each voxel (x,y,z) in the original image, the position  $(x+\Delta_x,y+\Delta_y,z+\Delta_z)$  after reregistration was computed. This position was determined by means of 3 self-constructed images in which neighboring voxels differed by 1 unit in the x, y, and z directions. The distance  $(\Delta_x^2+\Delta_y^2+\Delta_z^2)^{1/2}$  was averaged over all rat brain voxels and used as a measure of accuracy.

# **General Statistics**

Regional intersubject and test–retest variability, as well as right-to-left asymmetry indices, were calculated from VOI-derived measurements of radioactivity concentration. The test–retest variability for radioligand index (relative metabolic activity and binding index)  $R_i$  in VOI region i was determined as  $|R_{i,1} - R_{i,2}| \times 2/(R_{i,1} + R_{i,2})$ , where the indices 1 and 2 refer to the 2 different scans of the same animal.

### **SPM**

A categoric subject design using conditions (disease vs. controls) was performed on parametric DAT and <sup>18</sup>F-FDG images of 3 individual 6OHDA-lesioned rats in comparison to the respective control data. Spatially normalized images were masked to remove extracerebral signal that would disrupt the global normalization for <sup>18</sup>F-FDG. All images were smoothed with a 16-mm isotropic gaussian kernel. SPM analysis of parametric DAT data was performed without global normalization, whereas for <sup>18</sup>F-FDG data, proportional scaling with a threshold of 0.8 of the maximum image intensity was applied (scaled to 50 mL/100 g/min). For statistical analysis, T-map data were interrogated at a peak

probability level of 0.001 (uncorrected) and an extent threshold of more than 50 voxels, unless indicated otherwise. Because of the conventional orientation in SPM2, the *x*-axis in the MRI template is negative to the right of the midline and positive to the left (6).

#### **RESULTS**

### Multitracer Small-Animal PET Probabilistic Atlases

Figure 4 shows the metabolic, DAT, and  $D_2$  receptor small-animal PET templates aligned in space with the rat brain atlas of Paxinos. The regional mean uptake, intersubject and test–retest variability, and right-to-left asymmetry indices of  $^{18}\text{F-FECT}$ ,  $^{11}\text{C-raclopride}$ , and  $^{18}\text{F-FDG}$  are displayed in Table 1.

As can be seen from these templates and Table 1, relative <sup>18</sup>F-FDG activity in the rat brain shows a fairly homogeneous and symmetric uptake in the cortex and brain stem and the highest relative activity in the cerebellum and inferior colliculus. The lowest uptake is seen in the medial temporal cortex, brain stem, and pituitary gland. Intersubject variation for <sup>18</sup>F-FDG ranged from 1.7% in the hippocampus and cerebral cortex to 6.4% in the pituitary gland. Regional test–retest values for metabolic normalized data were slightly lower, with a range from 0.6% in the hippocampus to 6.1% in the pituitary gland. Right-to-left ratio ranged from 0.963 (±0.017) in the temporal medial cortex to 1.013 (±0.009) in the cerebellum.


As for <sup>11</sup>C-raclopride, caudate-putamen binding is on average 2.45, with an SD of 0.27, which is comparable to the situation in humans, where a factor of 2.35 is found in healthy subjects (20). Modest uptake is also seen in the brain stem, including the inferior colliculus. The test–retest variability of the caudate-putamen was on the same order as intersubject variability for <sup>11</sup>C-raclopride, namely 14.0% and 11.0%, respectively.

<sup>18</sup>F-FECT shows a high binding index of almost 9 and a relatively low intersubject variation of 5.3%. Test–retest variability was 7.7% for the caudate-putamen and 10.4% for the nucleus accumbens. The values of test–retest variability for <sup>18</sup>F-FECT and <sup>11</sup>C-raclopride were determined in a small sample, which is likely to give conservative values.

### **Registration Accuracy**

Table 2 summarizes mean registration errors obtained when comparing guided misaligned MAP PET image volumes from a control and a 6OHDA-lesioned animal with their original spatially normalized image volumes. All results are reported in real distances (scaling factor of the images in SPM taken into consideration, so the reconstructed pixel size is actually 0.2 mm).

For the control animal, in all cases, the best results were obtained for <sup>11</sup>C-raclopride and <sup>18</sup>F-FDG data, whereas <sup>18</sup>F-FECT data showed the largest registration errors, likely because of the absence of a very specific signal outside the striatum. For <sup>11</sup>C-raclopride, the average translation and rotation errors were both 0.238 mm (range, 0.056–0.526



**FIGURE 4.** (A) Series of axial sections (ventral to dorsal; slice interval, 1.2 mm; radiologic orientation) through rat brain MRI atlas (top row) and coregistered small-animal PET templates. (B) One representative coronal (radiologic orientation) and sagittal slice through striatum. (C) Horizontal section through variance map at level z=-5.8 (relative to bregma). Color bars indicate relative intensities for <sup>18</sup>F-FDG and binding indices for DAT and D<sub>2</sub> ligands. Note higher uptake of <sup>18</sup>F-FDG in inferior colliculus, visualization of D<sub>2</sub> receptors in rat midbrain, and availability of DAT in substantia nigra (arrows). RAC = raclopride.

mm), whereas the average combination and linear stretching errors were 0.252 mm (combination range, 0.051–0.558 mm; linear stretching range, 0.054–0.564 mm). In comparison, larger registration errors occurred after linear stretching and combined transformations for an <sup>18</sup>F-FDG image volume: 0.344 mm (range, 0.002–0.796 mm) and 0.344 mm (range, 0.002–0.779 mm), respectively. The average <sup>18</sup>F-FDG translation and rotation errors were both 0.348 mm (range, 0.003–0.772 mm). For <sup>18</sup>F-FECT, the average combined error was 0.416 mm (range, 0.017–1.113 mm), whereas the average linear stretching error was 0.428 mm (range, 0.011–1.195 mm). The average <sup>18</sup>F-FECT translation and rotation errors were 0.428 mm (range, 0.020–1.080 mm) and 0.427 mm (range, 0.020–1.080 mm).

Reregistration of randomly misaligned data to the ligand-specific templates was less accurate for 6OHDA-lesioned rat data in comparison to control data, because of the induced lesion and the corresponding functional alterations, which result in asymmetric image information. The largest registration error was obtained for <sup>18</sup>F-FECT data. The average combined error was 0.862 mm (range, 0.003–2.601 mm), whereas the average linear stretching error was 0.812 mm (range, 0.004–4.244 mm). The average <sup>18</sup>F-FECT translation and rotation errors were 0.734 mm (range, 0.011–1.514 mm) and 0.712 mm (range, 0.001–1.920 mm), respectively. Reregistration of one <sup>18</sup>F-FECT MAP image volume with the highest rotation values failed, and this outlier result was excluded. For <sup>18</sup>F-FDG, the average translation and rotation errors were both 0.580 mm (trans-

lation range, 0.089–1.545 mm; rotation range, 0.089–1.544 mm), whereas the average combination and linear stretching errors were 0.577 mm (range, 0.087–1.573 mm) and 0.585 mm (range, 0.084–1.630 mm), respectively.

# SPM Analysis of 6OHDA-Lesioned Rat Model

Statistical parametric maps from the metabolic/presynaptic dopaminergic characterization of individual 6OHDA-lesioned rats, compared with the control group, are shown in Figure 5. A highly significant reduction in DAT availability in the right striatum is seen in the lesioned rats, compared with the controls ( $P \le 0.0005$ , corrected for multiple comparisons; Paxinos coordinate peak maximum, (x,y,z) = (-3.8, -0.8, -5.8) for all subjects). The intensity of the deficit (percentage change in right striatal binding index vs. controls) was 99.4%, 98.0%, and 95.4% for the 3 animals.

Also, a significant glucose hypometabolism was noted in comparison to controls in the right sensorimotor cortex ( $P \le 0.0004$ ; peak maximum, (-3.6, 0.8, -2.0), (-3.4, 0.4, -2.0), (-3.4, 0.8, -2.0) for subjects A, B, and C, respectively). The mean glucose metabolic decrease was 10.0% versus controls (-12.1%, -8.3%, and -8.8% for subjects A, B, and C, respectively).

# DISCUSSION

This work evaluates the construction of MRI-based functional templates of the rat brain in Paxinos standard space and their application to automated standardized

TABLE 1

Mean Uptake, Intersubject Variability, Test-Retest, and Right-to-Left Asymmetry Indices Obtained
Using Predefined VOI Analysis

Region	Mean	SD	Intersubject (%)	Test-retest (%)	R/L ratio	SD	Volume (cm <sup>3</sup> )
<sup>18</sup> F-FDG (whole-brain normalized uptake)							
Cerebral cortex	0.996	0.017	1.7	2.6	0.998	0.004	0.312
Frontal cortex	1.045	0.034	3.3	2.7	0.994	0.007	0.134
Sensorimotor cortex	1.070	0.021	1.9	2.8	0.999	0.005	0.105
Temporal lateral cortex	0.949	0.032	3.3	2.0	0.997	0.018	0.013
Temporal medial cortex	0.881	0.023	2.6	1.2	0.963	0.017	0.060
Hippocampus	0.979	0.016	1.7	0.6	0.987	0.006	0.115
Hypothalamus	0.912	0.025	2.7	2.3	0.984	0.012	0.027
Pituitary gland	0.807	0.052	6.4	6.1	0.989	0.022	0.003
Caudate-putamen	1.022	0.020	2.0	1.4	0.983	0.010	0.085
Lateral globus pallidus	0.972	0.019	1.9	1.4	0.990	0.014	0.009
Medial globus pallidus	0.999	0.020	2.0	2.6	0.999	0.016	0.001
Thalamus	1.095	0.031	2.9	1.9	1.002	0.008	0.055
Pons	0.988	0.022	2.3	2.4	0.977	0.011	0.005
Cerebellum	1.007	0.028	2.7	5.4	1.013	0.009	0.253
Nucleus accumbens	0.995	0.022	2.3	1.6	0.995	0.017	0.011
<sup>11</sup> C-Raclopride binding index							
Caudate-putamen	2.451	0.271	11.0	14.0	0.985	0.050	
Nucleus accumbens	1.645	0.233	14.2	8.5	1.066	0.068	
<sup>18</sup> F-FECT binding index							
Caudate-putamen	8.888	0.473	5.3	7.7	0.994	0.018	
Nucleus accumbens	6.975	0.674	9.7	10.4	1.051	0.066	

analyses—using both a predefined-VOI approach and an SPM approach—of small-animal PET studies. This work also highlights the exemplary use of both analysis approaches by means of regional variability assessment and SPM analysis of pathologic data. The intersubject and test-retest variation, as well as the registration errors obtained in this study, indicate that accuracy comparable to that in the human situation can be achieved.


The total number of resolution elements in the rat brain (weighing about 1-2 g (21)) is limited to a few hundred calculated from a resolution of 1.5 mm in full width at half maximum. It is therefore of the utmost importance

that the amount of information be used maximally in these functional images. The limitations of operator-dependent ROI or VOI approaches are well known (10). The optimal way to maximize performance is by using a data-driven approach such as SPM, whereas in some instances—for reasons of a priori hypotheses or for sensitivity reasons—a predefined-VOI approach may be preferred (22). In both cases, added variability through inter- and intraobserver subjectivity in placement of regions is eliminated.

In our approach, use of an average small-animal MRI template, aligned in space with the rat brain Paxinos atlas,

**TABLE 2**Estimates of Registration Accuracy for Tracers and Animals Used in This Study After Reregistration of Randomly Misaligned Data

	1:	<sup>8</sup> F-FECT	<sup>11</sup> C-	Raclopride	<sup>18</sup> F-FDG	
Parameter	Mean	Range	Mean	Range	Mean	Range
Control animal						
Translation	0.428	0.020-1.080	0.238	0.056-0.526	0.348	0.003-0.772
Rotation	0.427	0.020-1.080	0.238	0.056-0.526	0.348	0.003-0.772
Linear stretching	0.428	0.011-1.195	0.252	0.054-0.564	0.344	0.002-0.796
Combined	0.416	0.017-1.113	0.252	0.051-0.558	0.344	0.002-0.77
Lesioned 60HDA animal						
Translation	0.734	0.011-1.514			0.580	0.089-1.54
Rotation	0.712	0.001-1.920			0.580	0.089-1.54
Linear stretching	0.812	0.004-4.244			0.585	0.084-1.630
Combined	0.862	0.003-2.601			0.577	0.087-1.573



**FIGURE 5.** Statistical parametric maps of 3 lesioned 6OHDA animals (1 animal each in A, B, and C). Differences for brain regions have been color coded and are superimposed on MRI template in 3 orthogonal planes. Sections with T-maps are rendered on MRI atlas of rat brain and show a significant reduction in DAT availability (top row) and glucose metabolism (bottom row). Colored bars on right express T-score levels. Intersection points of 3 planes have been set to position of maximum (i.e., (x,y,z) = (-3.8, -0.8, -5.8), Paxinos coordinates), which corresponds to right striatum.

allows the reporting of SPM results in coordinates directly corresponding to the Paxinos coordinate system, as well as an accurate definition of all major VOI structures because of the direct relationship between the coordinates of the Paxinos atlas and the MRI template voxels (6).

The constructed probabilistic PET atlases were averaged from several female Wistar rats. However, because of the similar anatomy for the given weight range, the atlases may also be used for spatial normalization of similar strains of rats or for the male sex (23), although the uptake values or binding indices might theoretically differ slightly because of changes in the menstrual cycle or other hormonal effects. These effects are second order for the current tracers when studied in humans and need to be investigated in more detail in rodents.

Validation of registration accuracy is of vital importance but often difficult. Determining registration errors by observer assessment and external fiducial markers has some drawbacks. As was our experience, reproducibility of animal positioning within a restraining or even stereotactic device proves to be insufficient for calibration purposes. The applied technique of reregistration of controlled misregistrations to evaluate the performance of a registration algorithm has been used in several studies (9,24). This technique assesses the robustness of the registration algorithm, thereby giving a realistic idea of the accuracy that can be obtained.

The automated spatial normalization procedure (12-parameter affine) integrated in SPM2 succeeded in obtain-

ing similar registration accuracies independent of the type of transformation applied a priori. Registration errors within the range of 0.24-0.86 mm indicate that a sufficient accuracy for novel animals can be achieved for subsequent quantitative analysis. The registration errors found in this study, both for normal and pathologic data, are in relative agreement with published human data when relative values are considered with respect to imaging resolution (e.g., corresponding to 2- to 3-mm accuracy for PET or SPECT devices with 4- to 10-mm resolution) (25). They are, however, higher than the values reported by Rubins et al., who found an accuracy of 0.05 mm and 0.05° using the mutualinformation algorithm to reregister misaligned PET images of the rat brain (9), but the accuracy was not clearly defined in their work and they applied translation and rotation separately on a single image. Moreover, the registration errors found in this work are even better than the errors obtained when using a stereotactic frame for repositioning the rat brain in serial PET studies (15).

Few reports have studied the implications of misalignments on quantitative measures in the (human) brain. Sychra et al. found that registration errors for single-axisshift differences of 0.7 mm and  $1^{\circ}$  of rotation may produce intensity errors of 5%–10% on the voxel level using a voxel size of 5.6 mm (26). However, this estimation produces a maximum possible error that is diminished by considering larger adjacent regions or clusters as is done with the SPM approach, where smoothing is the standard applied technique to level out intersubject anatomic differences in the

spatial normalization method. Therefore, it is expected that VOI analysis and statistical voxel-based analysis will result in significantly lower (semi)quantitative errors.

The mean translation, rotation, linear stretching, and combination errors found for the control animal in this work were strongly dependent on the radioligand used. The striatal specific uptake and the global cerebral aspecific distribution of raclopride, with the exception of some midbrain areas, proved to be superior in registration accuracy. On the opposite side, <sup>18</sup>F-FECT uptake is characterized by a high signal-to-noise ratio and poor anatomic information because of the high specificity of the ligand used. Lesion induction and corresponding functional alterations resulted in less accurate registrations for the radioligands used, but still below the system resolution and comparable to pathologic human data.

The reported intersubject variability comprises image registration error, true nonlinear anatomic differences among the individual rat brains, and functional differences. In humans, variations in anatomy are often reduced by applying nonlinear warping techniques during spatial normalization, whereas in this study only affine transformations were applied. In this work, we have not yet considered applying nonlinear deformations because these need to be validated in detail for the rat brain, especially lesioned brains (27). Test-retest coefficients of variation, shown in Table 1, are consistent in magnitude with published measurements in humans (28-30) and in animal pilot studies using <sup>123</sup>I-N-ω-fluoropropyl-2-βcarboxymethoxy-3β-(4-iodophenyl)nortropane small-animal SPECT (31) and <sup>11</sup>C-raclopride small-animal PET (32). This finding confirms the possible utility of small-animal imaging as a precise molecular biomarker tool for longitudinal evaluation, such as in studies of disease progression or after neuromodulatory interventions. In view of the known negative aging effect of dopamine D<sub>2</sub> receptor expression (33) and the possibility of additional environmental influences, the relatively long interval between <sup>11</sup>C-raclopride PET scans (average, 10 wk) can be seen as a conservative estimate for the reproducibility of <sup>11</sup>C-raclopride imaging in rats.

Examination of the intersubject and test–retest variability of template VOI measurements only within our method may not provide insight into the accuracy of the template method itself, because variability reflects several factors other than the accuracy of registration. Previous studies have compared intersubject and test–retest variability values between template-based methods and the traditional individual VOI method without using templates. In control animals, Rubins et al. (9) found a significant decrease in right–left binding index differences using their cryosectioned atlas-derived VOI method than using manually drawn ROIs. The test–retest variability was also lower using an atlasderived VOI method. Moreover, reduced intersubject and test–retest variability by atlas-derived methods has been demonstrated repeatedly for human brain imaging.

Additionally, we demonstrated the feasibility of using the functional rat brain templates in an experiment to charac-

terize metabolic/dopaminergic alterations in a 6OHDA rat model of acute Parkinson's disease. The reduction in striatal DAT binding is a well-known feature in 6OHDA-lesioned rats, primarily validated using invasive histologic and electrophysiologic analysis (34), and correlates to the nigrostriatal dopaminergic damage inflicted by toxin administration (35). Additionally, a metabolic decrease in the ipsilateral sensorimotor cortex was found, pointing to a hypofunctional striatocortical network that corresponds to corticosubcortical network findings in humans (36). This feasibility substudy therefore shows that multitracer small-animal PET is a promising and sensitive tool for evaluations of rat models of brain disease and translational investigations of correspondence to human disease.

An important limitation of the study, and an issue for further research, is correction for the partial-volume effect (37). At present, even the relatively high resolution of the microPET Focus 220 precludes detailed functional brain scanning in mice for most applications. Nevertheless, the availability of multiple transgenic mouse models for various neurologic disorders would allow the neuroimaging community to take a giant leap into functional characterization of these widely studied and well-characterized genetically induced disease models. Also, for identification of activity in smaller nuclei centrally in the rat brain, partialvolume-effect corrections would be advantageous. For such applications, first, the issues of (automated) intermodality high-resolution small-animal PET-to-MRI registration need to be resolved, and segmentation algorithms need to be optimized for rodent brains. Then, algorithms for partialvolume-effect correction that have been developed for human brain imaging (38,39) could be extended to use in rodents.

In comparison to human studies, the animals in this study received a relatively high dose of radiotracer. Because the average weight of humans versus rats has a ratio of approximately 300, care needs to be taken not to induce pharmacologic effects. For the specific activity administered, the calculated percentage receptor occupancy of <sup>11</sup>C-raclopride ranged from 0.4% to 8%. This range is still unlikely to induce a major pharmacologic effect, such as dyskinesia, which is observed at an occupancy of over 50% for dopamine D<sub>2</sub> receptors (40).

## CONCLUSION

Functional rat brain templates in stereotactic Paxinos coordinate space allow automatic anatomic standardization of anatomic and functional rat brain scans with the necessary registration accuracy and the standardization of predefined VOI or SPM analysis. Because test–retest and intersubject variability are comparable to the human situation, a path is formed for precise interventional or longitudinal studies in the rat brain for disease characterization or treatment response.

### **ACKNOWLEDGMENTS**

We thank Erwin Lauwers for invaluable help with animal preparation; Marva Bex, Tjibbe de Groot, and Dominique Vanderghinste for radiopharmaceutical preparation; and Patrick Dupont for advice on data handling. This work is financially supported by the Research Council of the Katholieke Universiteit Leuven (OT/05/58), the Flemish Research Foundation FWO (G.0548.06), and the Institute for Science and Technology SBO (AniMoNe) and is conducted under the European Community FP6 Network-of-Excellence DiMI (LSHB-CT-2005-512146)/EMIL (LSHC-CT-2004-503569).

### **REFERENCES**

- Lythgoe MF, Sibson NR, Harris NG. Neuroimaging of animal models of brain disease. Br Med Bull. 2003;65:235–257.
- 2. Brown V, Smith D. Mouse models of madness. Mol Psychiatry. 1999;4:400-402.
- Fox PT, Perlmutter JS, Raichle ME. A stereotactic method of anatomical localization for positron emission tomography. J Comput Assist Tomogr. 1985; 9:141–153.
- Sugiura M, Kawashima R, Sadato N, et al. Anatomic validation of spatial normalization methods for PET. J Nucl Med. 1999;40:317–322.
- Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Orlando, FL: Academic Press: 1998.
- Schweinhardt P, Fransson P, Olson L, Spenger C, Andersson JL. A template for spatial normalisation of MR images of the rat brain. *J Neurosci Methods*. 2003;129:105–113.
- Black KJ, Snyder AZ, Koller JM, Gado MH, Perlmutter JS. Template images for nonhuman primate neuroimaging: 1. Baboon. *Neuroimage*. 2001;14:736–743.
- Greer PJ, Villemagne VL, Ruszkiewicz J, et al. MR atlas of the baboon brain for functional neuroimaging. *Brain Res Bull*. 2002;58:429–438.
- Rubins DJ, Melega WP, Lacan G, et al. Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain. Neuroimage. 2003;20:2100–2118.
- Van Laere KJ, Warwick J, Versijpt J, et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. J Nucl Med. 2002;43:458–469.
- Nikolaus S, Larisch R, Beu M, Forutan F, Vosberg H, Muller-Gartner HW. Bilateral increase in striatal dopamine D<sub>2</sub> receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging. 2003;30:390–395.
- Wilson AA, DaSilva JN, Houle S. In vivo evaluation of [<sup>11</sup>C]- and [<sup>18</sup>F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. *Nucl Med Biol.* 1996;23:141–146.
- Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D<sub>2</sub> dopamine receptor binding in the living human brain by PET. Science. 1986;231: 258, 261
- Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. *Ann Neurol*. 1979;6: 371–388
- Rubins DJ, Meadors AK, Yee S, Melega WP, Cherry SR. Evaluation of a stereotactic frame for repositioning of the rat brain in serial positron emission tomography imaging studies. J Neurosci Methods. 2001;107:63–70.
- Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH. High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. *Phys Med Biol.* 1998;43:1001–1013.
- Chatziioannou A, Qi J, Moore A, et al. Comparison of 3-D maximum a posteriori and filtered backprojection algorithms for high-resolution animal imaging with microPET. IEEE Trans Med Imaging. 2000;19:507–512.

- Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. *IEEE Trans Med Imaging*. 1997;16:187–198.
- Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096– 1112.
- Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol. 1995;52:1183–1190.
- Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol. 2005;32:673–678.
- Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998; 25:663–667
- Paxinos G, Watson C, Pennisi M, Topple A. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods. 1985:13:139–143.
- Van Laere K, Koole M, D'Asseler Y, et al. Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. J Nucl Med. 2001;42:361–375.
- Eberl S, Kanno I, Fulton RR, Ryan A, Hutton BF, Fulham MJ. Automated interstudy image registration technique for SPECT and PET. J Nucl Med. 1996; 37:137–145.
- Sychra JJ, Pavel DG, Chen Y, Jani A. The accuracy of SPECT brain activation images: propagation of registration errors. Med Phys. 1994;21:1585–1590.
- Fiez JA, Damasio H, Grabowski TJ. Lesion segmentation and manual warping to a reference brain: intra- and interobserver reliability. *Hum Brain Mapp*. 2000:9:192–211.
- Tsuchida T, Ballinger JR, Vines D, et al. Reproducibility of dopamine transporter density measured with <sup>123</sup>I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med. 2004;18:609–616.
- Volkow ND, Fowler JS, Wang GJ, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med. 1993;34:609–613.
- Tyler JL, Strother SC, Zatorre RJ, et al. Stability of regional cerebral glucose metabolism in the normal brain measured by positron emission tomography. J Nucl Med. 1988;29:631–642.
- Booij J, de Bruin K, De Win MM, Lavini C, Den Heeten GJ, Habraken JB. Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. *Nucl Med Biol*. 2003;30:643–649.
- Alexoff DL, Vaska P, Marsteller D, et al. Reproducibility of <sup>11</sup>C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. *J Nucl Med.* 2003;44:815–822.
- O'Boyle KM, Waddington JL. Loss of rat striatal dopamine receptors with ageing is selective for D-2 but not D-1 sites: association with increased nonspecific binding of the D-1 ligand [3H]piflutixol. Eur J Pharmacol. 1984; 105:171–174.
- Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996;50:275

  –331.
- Lauwers E, Beque D, Van Laere K, et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. *Neurobiol Aging*. January 16, 2006 [Epub ahead of print].
- Strafella AP, Ko JH, Grant J, Fraraccio M, Monchi O. Corticostriatal functional interactions in Parkinson's disease: a rTMS/[<sup>11</sup>C]raclopride PET study. Eur J Neurosci. 2005;22:2946–2952.
- Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr. 1979;3:299–308.
- Baete K, Nuyts J, Van Laere K, et al. Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. *Neuroimage*. 2004; 23:305–317.
- Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRIbased correction for partial volume effects. *J Cereb Blood Flow Metab.* 1992; 12:571–583.
- Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol. 2005;32:673–678.